Gaithersburg, Md – Feb 27 2025
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a leading AI-driven drug development company, has announced a strategic collaboration with Eleison Pharmaceuticals to enhance clinical trial efficiency using artificial intelligence. Under this agreement, Eleison will leverage BullFrog Data Networks™ to optimize patient clustering, improve safety analysis, and refine clinical trial design for glufosfamide, an investigational treatment for pancreatic cancer.
Enhancing Trial Efficiency with AI
The collaboration will apply BullFrog AI’s bfLEAP® technology, a proprietary AI-driven platform designed to extract insights from complex clinical datasets. By integrating AI analytics into Eleison’s ongoing Phase 3 trial, the companies aim to identify predictive biomarkers, improve patient stratification, and streamline trial execution.
“This collaboration highlights the growing role of AI in clinical trials,” said Vin Singh, CEO of BullFrog AI. “By leveraging our technology, Eleison can enhance patient selection, optimize trial design, and accelerate drug development.”
Addressing Unmet Needs in Pancreatic Cancer
Glufosfamide, a third-generation alkylating agent, is being evaluated in a pivotal Phase 3 randomized clinical trial as a second-line treatment for pancreatic cancer. With pancreatic cancer ranking as the third leading cause of cancer-related deaths in the U.S., this partnership aims to drive innovation in oncology drug development where new therapeutic options are urgently needed.
“Our collaboration with BullFrog AI aligns with our mission to develop breakthrough cancer therapies,” said Edwin Thomas, CEO of Eleison Pharmaceuticals. “AI-driven insights will enhance our ability to monitor safety signals and refine our broader oncology pipeline.”
Future Implications
Beyond glufosfamide, the AI-driven insights from this collaboration will support Eleison’s clinical development of other investigational treatments, including inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The partnership underscores the potential of AI to improve trial efficiency, reduce failure rates, and accelerate the delivery of life-saving medicines.
About BullFrog AI
BullFrog AI is an AI-powered drug development company dedicated to reducing clinical trial failure rates through machine learning and causal AI. The company’s proprietary bfLEAP® platform extracts actionable insights from complex biological data to drive more efficient therapeutic development.
By
